ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "7b71057f-4c62-4632-a662-5fdcd724cc6f"}, "_deposit": {"id": "20861", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "20861"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00020861", "sets": ["1787"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "480", "bibliographicPageStart": "475", "bibliographicVolumeNumber": "77", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "This study was designed to elucidate the predictive usefulness of the response evaluation criteria in solid tumors (RECIST), a volume response (VR; a \u003e 50% reduction in the tumor volume) and the post-neoadjuvant therapy maximum standardized uptake value (post-SUVmax) in patients with non-small cell lung cancer (NSCLC) after neoadjuvant therapy. Between December 2006 and June 2012, 33 patients with clinical stage II and III NSCLC who underwent pulmonary resection following neoadjuvant therapy were enrolled. The relationships between the variables and a pathological complete response (pCR), the disease-free survival (DFS) and the overall survival (OS) were analyzed. As neoadjuvant therapy, 24 patients received chemoradiotherapy, five patients received chemotherapy and four patients were given radiation therapy. Based on the RECIST, 12 tumors were classified as having a partial response and 21 tumors were classified as stable disease. Twenty-one tumors showed a VR and 12 did not. Twenty-five tumors had a post-SUVmax ≤7.5 and eight had a post-SUVmax \u003e7.5. Eight tumors had a pCR. In the multivariate Cox regression analysis, both a non-VR and a post-SUVmax \u003e7.5 were significant variables predicting the DFS (p = 0.0422 and 0.0127, respectively), but either was not for OS. The post-SUVmax was also a significant variable for the pCR rate (p = 0.0067). The post-treatment SUVmax can be a valid alternative variable that can be used to predict the effect of neoadjuvant therapy and the survival of patients with stage II and III NSCLC.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "URI", "subitem_identifier_uri": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/773.html"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/22991"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.77.3.475", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ozeki, Naoki"}], "nameIdentifiers": [{"nameIdentifier": "60433", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawaguchi, Koji"}], "nameIdentifiers": [{"nameIdentifier": "60434", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukui, Takayuki"}], "nameIdentifiers": [{"nameIdentifier": "60435", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukumoto, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "60436", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Shota"}], "nameIdentifiers": [{"nameIdentifier": "60437", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okasaka, Toshiki"}], "nameIdentifiers": [{"nameIdentifier": "60438", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yokoi, Kohei"}], "nameIdentifiers": [{"nameIdentifier": "60439", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-02-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "27_Ozeki.pdf", "filesize": [{"value": "310.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 310500.0, "url": {"label": "27_Ozeki.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/20861/files/27_Ozeki.pdf"}, "version_id": "d9752633-4538-4f2b-a3f9-4703d8e55b11"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "neoadjuvant therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "tumor volume", "subitem_subject_scheme": "Other"}, {"subitem_subject": "SUVmax", "subitem_subject_scheme": "Other"}, {"subitem_subject": "PET", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Which variables should be considered in patients with stage II and III non-small cell lung cancer after neoadjuvant therapy ?", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Which variables should be considered in patients with stage II and III non-small cell lung cancer after neoadjuvant therapy ?"}]}, "item_type_id": "9", "owner": "1", "path": ["1787"], "permalink_uri": "https://doi.org/10.18999/nagjms.77.3.475", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-09-07"}, "publish_date": "2015-09-07", "publish_status": "0", "recid": "20861", "relation": {}, "relation_version_is_last": true, "title": ["Which variables should be considered in patients with stage II and III non-small cell lung cancer after neoadjuvant therapy ?"], "weko_shared_id": null}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 77(3)

Which variables should be considered in patients with stage II and III non-small cell lung cancer after neoadjuvant therapy ?

https://doi.org/10.18999/nagjms.77.3.475
https://doi.org/10.18999/nagjms.77.3.475
7e0eb3eb-fb15-454f-8bd5-641e5126982f
名前 / ファイル ライセンス アクション
27_Ozeki.pdf 27_Ozeki.pdf (310.5 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2015-09-07
タイトル
タイトル Which variables should be considered in patients with stage II and III non-small cell lung cancer after neoadjuvant therapy ?
著者 Ozeki, Naoki

× Ozeki, Naoki

WEKO 60433

Ozeki, Naoki

Search repository
Kawaguchi, Koji

× Kawaguchi, Koji

WEKO 60434

Kawaguchi, Koji

Search repository
Fukui, Takayuki

× Fukui, Takayuki

WEKO 60435

Fukui, Takayuki

Search repository
Fukumoto, Koichi

× Fukumoto, Koichi

WEKO 60436

Fukumoto, Koichi

Search repository
Nakamura, Shota

× Nakamura, Shota

WEKO 60437

Nakamura, Shota

Search repository
Okasaka, Toshiki

× Okasaka, Toshiki

WEKO 60438

Okasaka, Toshiki

Search repository
Yokoi, Kohei

× Yokoi, Kohei

WEKO 60439

Yokoi, Kohei

Search repository
キーワード
主題Scheme Other
主題 lung cancer
キーワード
主題Scheme Other
主題 neoadjuvant therapy
キーワード
主題Scheme Other
主題 tumor volume
キーワード
主題Scheme Other
主題 SUVmax
キーワード
主題Scheme Other
主題 PET
抄録
内容記述 This study was designed to elucidate the predictive usefulness of the response evaluation criteria in solid tumors (RECIST), a volume response (VR; a > 50% reduction in the tumor volume) and the post-neoadjuvant therapy maximum standardized uptake value (post-SUVmax) in patients with non-small cell lung cancer (NSCLC) after neoadjuvant therapy. Between December 2006 and June 2012, 33 patients with clinical stage II and III NSCLC who underwent pulmonary resection following neoadjuvant therapy were enrolled. The relationships between the variables and a pathological complete response (pCR), the disease-free survival (DFS) and the overall survival (OS) were analyzed. As neoadjuvant therapy, 24 patients received chemoradiotherapy, five patients received chemotherapy and four patients were given radiation therapy. Based on the RECIST, 12 tumors were classified as having a partial response and 21 tumors were classified as stable disease. Twenty-one tumors showed a VR and 12 did not. Twenty-five tumors had a post-SUVmax ≤7.5 and eight had a post-SUVmax >7.5. Eight tumors had a pCR. In the multivariate Cox regression analysis, both a non-VR and a post-SUVmax >7.5 were significant variables predicting the DFS (p = 0.0422 and 0.0127, respectively), but either was not for OS. The post-SUVmax was also a significant variable for the pCR rate (p = 0.0067). The post-treatment SUVmax can be a valid alternative variable that can be used to predict the effect of neoadjuvant therapy and the survival of patients with stage II and III NSCLC.
内容記述タイプ Abstract
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.77.3.475
ID登録タイプ JaLC
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
書誌情報 Nagoya Journal of Medical Science

巻 77, 号 3, p. 475-480, 発行日 2015-08
著者版フラグ
値 publisher
URI
識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/773.html
識別子タイプ URI
URI
識別子 http://hdl.handle.net/2237/22991
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 15:38:10.337979
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3